首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 8期 遗传性肝病的诊断 => 综述 =>肝细胞癌综合治疗的现..
肝细胞癌综合治疗的现状和前景
Current status and perspectives of multimodality therapy for hepatocellular carcinoma
文章发布日期:2019年07月05日  来源:  作者:谭运华, 商阳阳, 张涛,等  点击次数:327次  下载次数:221次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:肝细胞癌(HCC)在全世界有很高的发病率和病死率,因为HCC发生发展的复杂性,到目前为止,HCC的管理策略尚未完全统一。特别近十年来,HCC的治疗方案已发展为以外科手术为主的多学科综合治疗。除了肝切除和肝移植以外,消融治疗是另外一种根治性治疗方法,目前针对肿瘤直径<3 cm且不能接受肝移植的肝癌患者,可作为一线治疗方案;肝动脉化疗栓塞术是针对不适合根治性治疗的中晚期肝癌的首选治疗方法,可联合消融治疗和化疗,显示出良好的疗效;对于诊断为晚期HCC或在其他治疗失败后进展到晚期HCC患者可以选择分子靶向治疗;细胞免疫治疗是HCC新型治疗方法,可以为进展性HCC患者带来有效的缓解率和生存获益。充分解析HCC各种治疗方法特点,制订个体化治疗方案,合理综合治疗HCC,以提高HCC整体疗效。
【Abstract】:Hepatocellular carcinoma (HCC) has high morbidity and mortality rates worldwide, and due to the complexity of the development of HCC, the management strategy for HCC has not been completely unified. During the past decade, the treatment of HCC has developed into a multidisciplinary and multimodality therapy centered on surgical operation. Besides hepatectomy and liver transplantation, ablation therapy is another radical treatment, and at present, it can be used as the first-line treatment regimen for HCC patients who have a tumor diameter of <3 cm and cannot undergo liver transplantation. Transarterial chemoembolization is the preferred treatment for advanced HCC not suitable for radical treatment. Molecular targeted therapy is mainly used in patients who are diagnosed with advanced HCC or progress to advanced HCC after treatment failures. Cellular immunotherapy is a new treatment for HCC and can help patients with progressive HCC to achieve good remission rate and survival benefit. A deep understanding of the features of each treatment method for HCC, development of individualized treatment regimens, and rational multimodality therapy for HCC can help to improve the overall therapeutic outcome of HCC.
【关键字】:癌, 肝细胞; 治疗学; 预后
【Key words】:carcinoma, hepatocellular; therapeutics; prognosis
【引证本文】:TAN YH, SHANG YY, ZHANG T, et al. Current status and perspectives of multimodality therapy for hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(8): 1858-1860. (in Chinese)
谭运华, 商阳阳, 张涛, 等. 肝细胞癌综合治疗的现状和前景[J]. 临床肝胆病杂志, 2019, 35(8): 1858-1860.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号